ÂÜÀòÂÒÂ×

Gil Beyen joined the company’s board of directors in 2015. Gil is the CEO of ERYTECH Pharma (Euronext and Nasdaq: ERYP), a position he has held since May 2013. Between 2000 and 2013, Gil was CEO of TiGenix (Euronext: TIG), a company he co-founded. He previously served as the head of the life sciences at Arthur D. Little, an international management consulting firm. Gil received an M.Sc. in Bioengineering from the Katholieke Universiteit Leuven and an MBA from the University of Chicago.